Recombinant Human VEGF 165 by Bio-Techne

Manufacturer Bio-Techne
R&D VEGF -Recombinant Human VEGF 165R Protein Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. Specifications and Use for R&D VEGF 165RSource of R&D VEGF• A DNA sequence encoding the 165 amino acid residue variant of human VEGF (Leung, D.W. et al., 1989, Science 246:1306) was expressed in Sf 21 insect cells using a baculovirus expression system.... Read more


Recombinant Human VEGF 165 by Bio-Techne product image
Recombinant Human VEGF 165

The supplier does not provide quotations for this particular product through SelectScience. You can search for similar products in our product directory.



0 Scientists have reviewed this product


Write the First Review

No Reviews

R&D VEGF -Recombinant Human VEGF 165R Protein

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult.

Specifications and Use for R&D VEGF 165R

Source of R&D VEGF
• A DNA sequence encoding the 165 amino acid residue variant of human VEGF (Leung, D.W. et al., 1989, Science 246:1306) was expressed in Sf 21 insect cells using a baculovirus expression system.
• Note: This is one of multiple forms available for this protein. Check R&D Systems' website, www.RnDSystems.com, for a complete listing of the variants.

Molecular Mass of R&D VEGF 
• The recombinant disulfide-linked homodimeric hVEGF is glycosylated and migrates as a 19 - 21 kDa protein in SDS-PAGE under reducing conditions.

Purity of R&D VEGF 
• > 97%, as determined by SDS-PAGE and visualized by silver stain.

Endotoxin Level
• < 1.0 EU per 1 μg of the cytokine as determined by the LAL method.

Activity of R&D VEGF 
• The biological activity of recombinant human VEGF was measured by its ability to induce proliferation of human umbilical vein endothelial cells (Conn, G. et al., 1990, Proc. Natl. Acad. Sci. USA 87:1323 - 1327).
• The ED50 for this effect is typically 2.0 - 6.0 ng/mL.

Formulation of R&D VEGF 
• Lyophilized from a 0.2 μm filtered solution in 30% acetonitrile and 0.1% TFA containing 50 μg of bovine serum albumin per 1 μg of cytokine.

Reconstitution of R&D VEGF
• It is recommended that sterile phosphate-buffered saline containing at least 0.1% human serum albumin or bovine serum albumin be added to the vial to prepare a stock solution of no less than 10 μg/mL of the cytokine.

Storage of R&D VEGF 
• Lyophilized samples are stable for up to twelve months from date of receipt at -20° C to -70° C.
• Upon reconstitution, this cytokine can be stored under sterile conditions at 2° - 8° C for one month or at -20° C to -70° C in a manual defrost freezer for three months without detectable loss of activity.
• Avoid repeated freeze-thaw cycles.